Hualan Biological Engineering Inc. (301207)
Market Open
10 Aug, 06:57
XSHE XSHE Primary ¥
18. 23
+0.14
+0.7739%
¥
10.08B Market Cap
22.59 P/E Ratio
2.4% Div Yield
6.06M Volume
0 Eps
¥ 18.09
Previous Close Want to track 301207 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
301207 trading today higher at ¥18.23, an increase of 0.7739% from yesterday's close, completing a monthly increase of 11.9779% or ¥1.95. Over the past 12 months, 301207 stock lost -2.252%.
301207 pays dividends to its shareholders, with the most recent payment made on Jun 15, 2026. The next estimated payment will be in In 4 months on Dec 15, 2026 for a total of ¥0.8.
The last earnings report, released on Oct 29, 2024, exceeded the consensus estimates by 0.4043%. On average, the company has surpassed earnings expectations by 0.2841%, based on the last three reports.
Hualan Biological Engineering Inc. has completed 1 stock splits, with the recent split occurring on Jun 07, 2023.
The company's stock is traded on one exchange.
301207 Chart
People also search for
Hualan Biological Engineering Inc. (301207) FAQ
What is the stock price today?
The current price is ¥18.23.
On which exchange is it traded?
Hualan Biological Engineering Inc. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 301207.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 2.4%.
What is its market cap?
As of today, the market cap is 10.08B.
Has Hualan Biological Engineering Inc. ever had a stock split?
Hualan Biological Engineering Inc. had 1 splits and the recent split was on Jun 07, 2023.
Hualan Biological Engineering Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ms. Wenjue An CEO | XSHE Exchange | CNE1000058J9 ISIN |
| CN Country | 708 Employees | 15 Jun 2026 Last Dividend | 7 Jun 2023 Last Split | - IPO Date |
Overview
Hualan Biological Bacterin Inc. is a prominent biopharmaceutical company based in Xinxiang, China, that has been pioneering in the field since 2005. The company is dedicated to the research, development, production, and sale of various vaccines within China. By focusing on innovative vaccines for human use, it aims to address some of the most pressing health issues and contribute significantly to the control of infectious diseases in the region.
Products and Services
- Influenza Virus Split Vaccines: These vaccines protect against seasonal influenza, using a virus that has been split or fragmented to stimulate an immune response without causing disease.
- Quadrivalent Influenza Virus Split Vaccines: This vaccine offers broader protection by targeting four different strains of the influenza virus, including two strains of Influenza A and two strains of Influenza B, enhancing its efficacy against the flu.
- H1N1 Influenza Virus Split Vaccines: Specifically formulated to combat the H1N1 strain of the influenza virus, also known as swine flu. This vaccine plays a crucial role in preventing outbreaks of this particular influenza variation.
- ACYW135 Meningococcal Polysaccharide Plague Vaccines: Designed to protect against four serogroups of meningococcal disease (A, C, Y, and W-135), these vaccines are crucial in preventing bacterial meningitis and septicemia, particularly in areas where these diseases are prevalent.
- Recombinant Hepatitis B Vaccines: Utilizes genetic engineering to produce components of the hepatitis B virus to elicit immunity, offering a high level of protection against hepatitis B, a potentially life-threatening liver infection.
- Group A and C Meningococcal Polysaccharide Vaccines: These vaccines provide immunization against groups A and C of the Neisseria meningitidis bacteria, which are among the leading causes of bacterial meningitis across the globe.
- Genetic Engineering Vaccines for Human Use: Hualan Biological Bacterin Inc. also focuses on the development and production of various genetically engineered vaccines. These vaccines employ cutting-edge biotechnological approaches to prevent a variety of infectious diseases, showcasing the company's commitment to innovation and healthcare advancement.
Contact Information
Address: Jia No. 1-1, Hualan Avenue, Xinxiang, China, 453003
Phone: 86 37 3355 9909
Website: https://www.hualanbacterin.com
